Company Analysis
Sign in

Ascendis Pharma A/S (ASND)

Nasdaq: ASND · Pharmaceutical Preparations · filing with the SEC since 2014
Full chart Alerts Compare
Grade6.2
◀ Past 7.0● Present 6.0▶ Future 5.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue€720M+98.0%
Net income-€228M+39.7%
Earnings per share€-3.76+42.4%
Operating cash flow€53.9M+117.6%
Cash€616M+10.1%
Debt€720M-5.7%
Shareholders’ equity-€163M-54.0%
Shares, diluted60.6M+4.7%
Return on equityn/a
The recordfrom its filings
Filings in 2026107
Newest filingNov 12 · 6-K
Annual reportFeb 11, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$5.5M
Insider buys, 12 months$800,000
Patents granted76
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in EUR. Nothing here is a forecast.

News

Sep 28, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ASND · research, not advice